Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASE1 | P07998 | 1/20 | 0.53 |
| ▸ | TOP2A | P11388 | 4/20 | 0.49 |
| ▸ | TK2 | O00142 | 3/20 | 0.46 |
| ▸ | TK1 | P04183 | 5/20 | 0.45 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL735094 | 0.89 | TOP2A (0.53) | RNASE1TOP2ATK1ABCG2ABCB1 | |
| SCHEMBL16494725 | 0.88 | RNASE1 (0.64) | RNASE1TOP2ATK2TK1ABCG2 | |
| SCHEMBL735281 | 0.85 | RNASE1 (0.55) | RNASE1TOP2ATK2TK1ABCG2 | |
| SCHEMBL733053 | 0.84 | TOP2A (0.48) | RNASE1TOP2ATK2TK1ABCG2 | |
| SCHEMBL25757662 | 0.83 | RNASE1 (0.51) | RNASE1TOP2ATK2TK1 | |
| SCHEMBL734481 | 0.83 | TOP2A (0.51) | RNASE1TOP2ATK1ABCG2ABCB1 | |
| SCHEMBL8180624 | 0.83 | TOP2A (0.54) | RNASE1TOP2ATK1 | |
| SCHEMBL9550741 | 0.82 | RNASE1 (0.52) | RNASE1TOP2ATK2TK1 | |
| SCHEMBL9550739 | 0.82 | RNASE1 (0.52) | RNASE1TOP2ATK2TK1 | |
| SCHEMBL8187063 | 0.82 | TOP2A (0.46) | RNASE1TOP2ATK1ABCG2ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138330-B2 | Solid phase synthesis via deblocking immobilized nucleoside, then coupling acyl protected nucleoside phosphoramidite | SIGMA-ALDRICH CO. LLC (US) | 2012-03-20 | — | — | US | disclosed |
| US-20080064867-A1 | PROCESS FOR THE SYNTHESIS OF OLIGONUCLEOTIDES | SIGMA ALDRICH COMPANY (US) | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064867-A1 | PROCESS FOR THE SYNTHESIS OF OLIGONUCLEOTIDES | RNGTT, DUT, ADAR | RNASE1 154/4885TOP2A 643/4885TK2 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.